TP53 and sarcoma: Since many fusion-driven sarcomas exhibit few or no co-occurring alterations, oncogenes were tested alone (together with an empty sgRNA vector) and in combination with sgRNAs targeting tumor suppressors, such as Trp53 to overcome oncogene-induced stress responses.